INOVIO reveals pricing details for $25 million public offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 11 2025
0mins
Source: SeekingAlpha
Public Offering Announcement: INOVIO Pharmaceuticals has priced an underwritten public offering of 13.15 million shares at $1.90 per share, with all shares being sold by the company.
Closing Date and Additional Options: The offering is expected to close around November 12, and underwriters have a 30-day option to purchase an additional 1,973,700 shares at the same price.
Expected Proceeds: The gross proceeds from the offering are anticipated to be approximately $25 million.
Market Reaction: Following the announcement, INO's stock dropped 6% in premarket trading, with shares priced at $2.005.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like INO with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INO is 7.33 USD with a low forecast of 3.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.610
Low
3.00
Averages
7.33
High
13.00
Current: 1.610
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inovalis REIT Completes Disposition of Trio Property
- Disposition Completed: Inovalis REIT announced the completion of the Trio property disposition, which had been reclassified as an asset held for sale in its financial statements as of September 30, 2025, and this transaction is expected to enhance financial stability.
- Loan Repayment: Proceeds from the disposition were used to repay the mortgage loan secured by the Trio property, with all related financing arrangements fully satisfied and discharged, thereby alleviating the REIT's financial burden.
- Occupancy Impact: At the time of disposition, the Trio property had an occupancy rate of approximately 40%, negatively impacting the REIT's cash flow, and this transaction is anticipated to improve overall cash flow conditions.
- LTV Reduction: The transaction reduced the REIT's overall loan-to-value (LTV) ratio by approximately 5% to 61.5%, aligning with its ongoing portfolio management strategy and reflecting a disciplined approach to asset management.
Continue Reading
Inovio Pharmaceuticals Under Investigation, Stock Plummets 24.45%
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Inovio Pharmaceuticals and its executives have engaged in securities fraud or other unlawful business practices, potentially leading to significant losses for investors.
- FDA Review Update: On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107, but the company failed to provide adequate information for accelerated approval, highlighting regulatory compliance challenges.
- Stock Price Volatility: Following the FDA's review outcome, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share on December 29, 2025, reflecting market pessimism about the company's future prospects.
- Uncertain Future Plans: Inovio announced it does not plan to seek approval under the standard review timeline and intends to meet with the FDA to discuss the possibility of accelerated approval, indicating uncertainty in its product launch strategy.
Continue Reading